Skip to main content
SpringerLink
Log in

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients

  • Clinical-patient studies
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 17 May 2008

An Erratum to this article was published on 08 February 2008

Abstract

The purpose of this study was to evaluate safety and efficacy of Procarbazine (PCB) and fotemustine (FTM) combination in the treatment of pre-temozolomide treated, recurrent GBM patients. The primary end-point was progression free survival at 6 months (PFS-6). Secondary end-points were overall survival, response rates (CR + PR) and toxicity. About 54 patients (41 men and 13 women) aged 26–68 years (median age, 53.5 years) with recurrent GBM were treated. PCB was administered as an oral dosage of 450 mg on days 1–2 and a total dose of 300 mg on day 3. FTM was administered on day 3, 3 h after the last PCB intake at a dose of 110 mg/mq/BSA. The treatment was repeated every 5 weeks. Treatment was continued for a maximum of six cycles or until disease progression. After two cycles of chemotherapy: 6 patients (11.2%) experienced a neuroradiographic partial response (PR), 29 patients (53.7%) had stable disease (SD), and 19 patients (35.1%) had progressive disease (PD). For the whole group of patients, the median PFS was 19.3 weeks (95% CI, 14.1–24.4 weeks), and PFS-6 was 26.7% (95% CI, 10.6–42.8%). Overall MST from the beginning of PCB + FTM chemotherapy was 28.7 weeks (95% CI, 24.8–32.7 weeks). At 6 and 12 months, 64.4% (95% CI, 51.5–77.3%) and 23.6% (95% CI, 10.1–37.1%) of patients were alive. The median survival time calculated from the first diagnosis was 20.8 months (95% CI, 16.7–24.8). We concluded that the PCB + FTM combination as done in the current trial for patients with recurrent GBM after treatment with TMZ showed some benefit with regards to increased survival and that a Phase III trial is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 7:259–266

    Article  Google Scholar 

  2. Simpson L, Galanis E (2006) Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. Expert Rev Anticancer Ther 6:1593–1607

    Article  PubMed  CAS  Google Scholar 

  3. Hau P, Baumgart U, Pfeifer K, Bock A, Jauch T, Dietrich J, Fabel K, Grauer O, Wismeth C, Klinkhammer-Schalke M, Allgauer M, Schuierer G, Koch H, Schlaier J, Ulrich W, Brawanski A, Bogdahn U, Steinbrecher A (2003) Salvage therapy in patients with glioblastoma: is there any benefit. Cancer 98:2678–2686

    Article  PubMed  Google Scholar 

  4. Vordermark D, Kolbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5:55

    Article  PubMed  Google Scholar 

  5. Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotacticfractionated radiotherapy. Int J Radiat Oncol Biol Phys 63:511–519

    PubMed  CAS  Google Scholar 

  6. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  7. Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593

    Article  PubMed  CAS  Google Scholar 

  8. Stupp R, Hegi ME, van den Bent MJ et al (2006) Changing paradigms—an update on the multidisciplinary management of malignant glioma. Oncologist 11:165–180

    Article  PubMed  CAS  Google Scholar 

  9. Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280

    PubMed  CAS  Google Scholar 

  10. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (2003) Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS ctep.cancer.gov/forms/CTCAEv3.pdf

  11. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10

    Article  PubMed  CAS  Google Scholar 

  12. Kaplan EL, Meier P (1958) Non parametric estimation for incomplete observation. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  13. Brandes AA, Tosoni A, Amistà P et al (2004) How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 63:1281–1284

    PubMed  CAS  Google Scholar 

  14. Boiardi A, Silvani A, Ciusani E et al (2001) Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation ofl ymphocyte 06-alkylguanine-DNA alkyltransferase activity. J Neurooncol 52:149–156

    Article  PubMed  CAS  Google Scholar 

  15. Brandes AA, Tosoni A, Cavallo G et al (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95(9):1155–1160

    Article  PubMed  CAS  Google Scholar 

  16. Pipas JM, Meyer LP, Rhodes CH et al (2005) A phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol 71:301–305

    Article  PubMed  CAS  Google Scholar 

  17. Silvani A, Eoli M, Salmaggi A et al (2004) Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J Neurooncol 66:203–208

    Article  PubMed  Google Scholar 

  18. Levin VA, Silver P, Hannigan J et al (1990) Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321–324

    PubMed  CAS  Google Scholar 

  19. Kappelle AC, Postma TJ, Taphoorn MJB et al (2001) PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56:118–120

    PubMed  CAS  Google Scholar 

  20. Nobile M, Laguzzi E, Rudà R et al (2006) Second-line PCV in recurrent or progressive glioblastomas: a phase II study. Abstracts for the Seventh Congress of the European Association for Neuro-Oncology (EANO). Neuroncol 8:354

    Google Scholar 

  21. Chamberlain MC, Tsao-Wei DD (2004) Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 100:1213–1220

    Article  PubMed  CAS  Google Scholar 

  22. Brandes AA, Tosoni A, Basso U et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22:4779–4786

    Article  PubMed  CAS  Google Scholar 

  23. Chamberlain MC, Kormanik P (1999) Salvage chemotherapy with Taxol for recurrent anaplastic astrocytomas. J Neurooncol 43:71–78

    Article  PubMed  CAS  Google Scholar 

  24. Sanson M, Napolitano M, Yaya R et al (2000). Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 50:245–249

    Article  PubMed  CAS  Google Scholar 

  25. Gertler SZ, MacDonald D, Goodyear M et al (2000) NCIC-CTG phase II study of gemcitabine in patients with malignant glioma. Ann Oncol 11:315–318

    Article  PubMed  CAS  Google Scholar 

  26. Prados M, Chang S, Burton E et al (2003) Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proc Am Soc Clin Oncol 22:99–104

    Google Scholar 

  27. Raizer JJ, Abrey LE, Wen P et al (2004) A phase II trial of erlotinib (OSI-774) in patients with recurrent malignant glioma not on EIAEDs. J Clin Oncol 22:107s

    Google Scholar 

  28. Meulemans A, Giroux B, Hannoun P et al (1989) Permeability of two nitrosoureas, carmustine and fotemustine, in rat cortex. Chemotherapy 35:313–319

    PubMed  CAS  Google Scholar 

  29. Levin VA (1980) Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 23:682–684

    Article  PubMed  CAS  Google Scholar 

  30. Frenay M, Giroux B, Khoury S et al (1991) Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer 27:852–856

    Article  PubMed  CAS  Google Scholar 

  31. Malhaire JP, Lucas B, Simon H et al (1999) Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas. French Bull Cancer 86:289–294

    CAS  Google Scholar 

  32. Laguzzi E, Rudà R, Trevisan E et al (2006) Efficacy of fotemustine in recurrent/progressive gliomas: a phase II study. Abstracts for the Seventh Congress of the European Association for Neuro-Oncology (EANO). Neuroncology 8:347

    Google Scholar 

  33. Pace A, Fabi A, Mirri A et al (2006) Second-line and third-line chemotherapy in malignant gliomas: is there a benefit? Abstracts for the Seventh Congress of the European Association for Neuro-Oncology (EANO). Neuroncology 8:346

    Google Scholar 

  34. Fazeny-Dorner B, Veitlb M, Wenzela C et al (2003) Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. AntiCancer Drugs 14:437–442

    Article  PubMed  Google Scholar 

  35. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296–307

    Article  PubMed  CAS  Google Scholar 

  36. Friedman HS (2000) Can O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic? Clin Cancer Res 6:2967–2968

    PubMed  CAS  Google Scholar 

  37. Raizer JJ, Malkin MG, Kleber M et al (2004) Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neurooncology 6:247–252

    CAS  Google Scholar 

  38. Tolcher AW, Gerson SL, Denis L et al (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004–1011

    Article  PubMed  CAS  Google Scholar 

  39. Chang SM, Prados MD, Yung WK et al (2004) Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium trial. Cancer 100:1712–1716

    Article  PubMed  CAS  Google Scholar 

  40. Prados MD, Yung WKA, Fine HA et al (2004) Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neurooncology 6:33–37

    CAS  Google Scholar 

  41. Massoud M, Armand JP, Ribrag V (2004) Procarbazine in haematology: an old drug with a new life? Eur J Cancer 40:1924–1927

    Article  PubMed  CAS  Google Scholar 

  42. Rodriguez LA, Prados M, Silver P et al (1989) Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 64:2420–2423

    Article  PubMed  CAS  Google Scholar 

  43. Newton HB, Junck L, Bromberg J et al (1990) Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 40:1743–1746

    PubMed  CAS  Google Scholar 

  44. Macdonald DR, Kiebert G, Prados M, Yung A, Olson J (2005) Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life Cancer Invest 23:138–144

    Article  PubMed  CAS  Google Scholar 

  45. Schold SC Jr, Brent TP, von Hofe E et al (1989) O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg 70:573–577

    Article  PubMed  Google Scholar 

  46. Beith J, Cook R, Robinson BLJ et al (1997) Modulation of resistance to BCNU by depleting MGMT activity with procarbazine in patients with relapsed high grade gliomas. Proc Am Assoc Cancer Res 16:386

    Google Scholar 

  47. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J Clin Oncol 17:2572–2578

    PubMed  CAS  Google Scholar 

  48. Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008–1012

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuro-oncology, Fondazione IRCCS Istituto Neurologico “ Carlo Besta”, Via Celoria, 11, Milan, 20133, Italy

    Antonio Silvani, Elena Lamperti, Paola Gaviani, Marica Eoli, Anna Fiumani, Andrea Salmaggi, Andrea Botturi & Amerigo Boiardi

  2. Neuro-epidemiology Unit, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Via Celoria, 11, Milan, 20133, Italy

    Chiara Falcone & Graziella Filippini

Authors
  1. Antonio Silvani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Lamperti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paola Gaviani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marica Eoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna Fiumani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrea Salmaggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chiara Falcone
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Graziella Filippini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Andrea Botturi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Amerigo Boiardi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Silvani.

Additional information

Two errata are available for this article; the first one at 10.1007/s11060-008-9539-z, the second one at 10.1007/s11060-008-9596-3.

An erratum to this article can be found at http://dx.doi.org/10.1007/s11060-008-9596-3

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silvani, A., Lamperti, E., Gaviani, P. et al. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J Neurooncol 87, 143–151 (2008). https://doi.org/10.1007/s11060-007-9427-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-007-9427-y

Keywords

Search

Navigation